419 | Humans |
203 | Coronavirus Infections (epidemiology) |
181 | Pneumonia, Viral (epidemiology) |
141 | Coronavirus Infections (transmission) |
132 | Animals |
127 | Pneumonia, Viral (transmission) |
99 | Coronavirus Infections (diagnosis) |
92 | Betacoronavirus |
91 | Female |
90 | Disease Outbreaks |
83 | Pneumonia, Viral (diagnosis) |
81 | Male |
80 | China (epidemiology) |
75 | Coronavirus Infections (prevention & control) |
68 | China |
67 | Pneumonia, Viral (prevention & control) |
65 | Betacoronavirus (pathogenicity) |
61 | Adult |
57 | Betacoronavirus (isolation & purification) |
56 | Coronavirus Infections (virology) |
55 | Middle Aged |
52 | Betacoronavirus (genetics) |
42 | Travel |
42 | Coronavirus Infections (complications) |
41 | Pneumonia, Viral (complications) |
38 | Pneumonia, Viral (virology) |
37 | Aged |
36 | Coronavirus Infections (therapy) |
35 | Pneumonia, Viral (therapy) |
34 | Pandemics |
32 | Public Health |
29 | Child |
28 | Phylogeny |
27 | Young Adult |
27 | Genome, Viral |
26 | Global Health |
24 | Pneumonia, Viral (drug therapy) |
23 | Lung (diagnostic imaging) |
23 | Coronavirus Infections (drug therapy) |
22 | Adolescent |
21 | Tomography, X-Ray Computed |
21 | Pneumonia, Viral (diagnostic imaging) |
21 | Disease Outbreaks (prevention & control) |
21 | Coronavirus Infections |
21 | Coronavirus Infections (pathology) |
20 | Coronavirus Infections (veterinary) |
20 | Coronavirus Infections (diagnostic imaging) |
20 | Antiviral Agents (therapeutic use) |
19 | Risk Factors |
19 | Retrospective Studies |
19 | Infant |
19 | Child, Preschool |
18 | Pneumonia, Viral |
18 | Fever (etiology) |
17 | Zoonoses |
17 | Time Factors |
17 | SARS Virus (genetics) |
17 | Radiography, Thoracic |
17 | Pneumonia, Viral (pathology) |
17 | Mice |
16 | World Health Organization |
16 | Severe Acute Respiratory Syndrome (epidemiology) |
16 | Coronavirus |
15 | Severe Acute Respiratory Syndrome (virology) |
15 | SARS Virus (pathogenicity) |
15 | Middle East Respiratory Syndrome Coronavirus |
15 | Lung (pathology) |
15 | Cattle |
15 | Antiviral Agents (pharmacology) |
15 | Aged, 80 and over |
14 | Population Surveillance |
14 | Infant, Newborn |
14 | Chiroptera (virology) |
14 | Amino Acid Sequence |
13 | Cough (etiology) |
12 | Rats |
12 | Pneumonia, Viral (mortality) |
12 | Coronavirus Infections (psychology) |
12 | Coronavirus (isolation & purification) |
12 | Contact Tracing |
11 | Respiratory Tract Infections (epidemiology) |
11 | Practice Guidelines as Topic |
11 | Pneumonia, Viral (etiology) |
11 | Infection Control |
11 | Epidemics |
11 | Coronavirus Infections (mortality) |
11 | Betacoronavirus (physiology) |
11 | Antibodies, Viral (blood) |
10 | Virus Replication |
10 | United States (epidemiology) |
10 | Severe Acute Respiratory Syndrome (diagnosis) |
10 | Republic of Korea |
10 | Real-Time Polymerase Chain Reaction |
10 | Pneumonia, Viral (psychology) |
10 | Patient Isolation |
10 | Pandemics (prevention & control) |
10 | Europe (epidemiology) |
10 | Coronavirus (genetics) |
10 | Betacoronavirus (drug effects) |
9 | Viral Proteins (genetics) |
9 | Severity of Illness Index |
9 | Severe Acute Respiratory Syndrome (transmission) |
9 | Sequence Alignment |
9 | Sensitivity and Specificity |
9 | SARS Virus |
9 | SARS Virus (immunology) |
9 | Risk Assessment |
9 | Respiratory Tract Infections (virology) |
9 | RNA, Viral (genetics) |
9 | Prognosis |
9 | Molecular Sequence Data |
9 | Models, Theoretical |
9 | Infection Control (methods) |
9 | Coronavirus Infections (immunology) |
9 | Civil Defense |
9 | Cell Line |
9 | Antibodies, Viral (analysis) |
9 | Age Factors |
8 | Virus Diseases (virology) |
8 | Virus Diseases (epidemiology) |
8 | Viral Proteins (chemistry) |
8 | Reverse Transcriptase Polymerase Chain Reaction |
8 | Republic of Korea (epidemiology) |
8 | Information Dissemination |
8 | Health Personnel |
8 | Disease Progression |
8 | Diagnosis, Differential |
8 | Antiviral Agents (chemistry) |
7 | Viral Vaccines (immunology) |
7 | United States |
7 | Swine |
7 | Structure-Activity Relationship |
7 | Spike Glycoprotein, Coronavirus |
7 | Severe Acute Respiratory Syndrome (pathology) |
7 | Respiratory Tract Infections (veterinary) |
7 | Respiration, Artificial |
7 | Protein Structure, Tertiary |
7 | Protein Binding |
7 | Prevalence |
7 | Pregnancy |
7 | Polymerase Chain Reaction |
7 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
7 | Internationality |
7 | Host-Pathogen Interactions |
7 | Health Planning |
7 | Emergencies |
7 | Dyspnea (etiology) |
7 | Cross-Sectional Studies |
7 | Communication |
7 | Communicable Diseases, Emerging |
7 | Cattle Diseases (epidemiology) |
7 | Australia (epidemiology) |
7 | Antigens, Viral (analysis) |
6 | Zoonoses (virology) |
6 | Species Specificity |
6 | Saudi Arabia (epidemiology) |
6 | SARS Virus (physiology) |
6 | SARS Virus (drug effects) |
6 | SARS Virus (chemistry) |
6 | Ritonavir (therapeutic use) |
6 | Respiratory Syncytial Virus Infections (epidemiology) |
6 | Quarantine |
6 | Public Health Surveillance |
6 | Pneumonia, Viral (veterinary) |
6 | Peptidyl-Dipeptidase A (metabolism) |
6 | Models, Molecular |
6 | Middle East Respiratory Syndrome Coronavirus (genetics) |
6 | Mental Health Services |
6 | Mass Screening |
6 | Lung (virology) |
6 | Lopinavir (therapeutic use) |
6 | Infectious Disease Incubation Period |
6 | Forecasting |
6 | Drug Design |
6 | Disease Transmission, Infectious |
6 | Disease Susceptibility |
6 | Disease Reservoirs (virology) |
6 | Coronavirus (classification) |
6 | Communicable Diseases, Emerging (virology) |
6 | Communicable Diseases, Emerging (epidemiology) |
6 | Cluster Analysis |
6 | Cattle Diseases (virology) |
6 | Cats |
6 | Betacoronavirus (immunology) |
6 | Betacoronavirus (classification) |
6 | Base Sequence |
6 | Antiviral Agents (chemical synthesis) |
6 | Algorithms |
6 | Air Travel |
5 | Zoonoses (transmission) |
5 | Zoonoses (epidemiology) |
5 | Viral Proteins (immunology) |
5 | Viral Load |
5 | Viral Envelope Proteins (chemistry) |
5 | Vero Cells |
5 | Travel Medicine |
5 | Taiwan |
5 | Surveys and Questionnaires |
5 | Spike Glycoprotein, Coronavirus (genetics) |
5 | Social Conditions |
5 | Severe Acute Respiratory Syndrome (therapy) |
5 | Severe Acute Respiratory Syndrome (prevention & control) |
5 | Severe Acute Respiratory Syndrome (diagnostic imaging) |
5 | Saudi Arabia |
5 | SARS Virus (isolation & purification) |
5 | Politics |
5 | Pneumonia |
5 | Peptidyl-Dipeptidase A (physiology) |
5 | Models, Statistical |
5 | Middle East Respiratory Syndrome Coronavirus (isolation & purification) |
5 | Medical History Taking |
5 | Infectious Disease Transmission, Patient-to-Professional |
5 | Incidence |
5 | Hospitalization |
5 | Health Services Accessibility |
5 | Fluorescent Antibody Technique |
5 | Fatigue (etiology) |
5 | Family Health |
5 | Drug Evaluation, Preclinical |
5 | Dogs |
5 | Disease Reservoirs |
5 | Disease Reservoirs (veterinary) |
5 | Disaster Planning |
5 | Delivery of Health Care |
5 | Databases, Genetic |
5 | Coronavirus Infections (genetics) |
5 | Coronaviridae (isolation & purification) |
5 | Coronaviridae (immunology) |
5 | Comorbidity |
5 | Clinical Trials as Topic |
5 | Chlorocebus aethiops |
5 | Cattle Diseases (diagnosis) |
5 | Biomarkers (blood) |
5 | Binding Sites |
5 | Betacoronavirus (metabolism) |
5 | Asymptomatic Infections |
5 | Alanine (analogs & derivatives) |
4 | Vulnerable Populations |
4 | Viruses (isolation & purification) |
4 | Virus Replication (drug effects) |
4 | Virus Diseases (veterinary) |
4 | Virus Cultivation |
4 | Virulence |
4 | Viral Proteins (metabolism) |
4 | Viral Envelope Proteins (genetics) |
4 | Universities |
4 | United Kingdom (epidemiology) |
4 | Uncertainty |
4 | T-Lymphocytes, Cytotoxic (immunology) |
4 | Spike Glycoprotein, Coronavirus (chemistry) |
4 | Severe Acute Respiratory Syndrome |
4 | Severe Acute Respiratory Syndrome (drug therapy) |
4 | Seroepidemiologic Studies |
4 | Seasons |
4 | Risk |
4 | Respiratory Tract Infections (microbiology) |
4 | Respiratory Distress Syndrome, Adult (virology) |
4 | Reproducibility of Results |
4 | Recombination, Genetic |
4 | RNA, Viral (analysis) |
4 | Protein Structure, Secondary |
4 | Pneumonia, Viral (immunology) |
4 | Pneumonia, Viral (genetics) |
4 | Pneumonia (virology) |
4 | Pneumonia (diagnosis) |
4 | Personal Protective Equipment |
4 | Peptides (chemistry) |
4 | Patient Care Planning |
4 | Neutralization Tests |
4 | Murine hepatitis virus (immunology) |
4 | Mortality |
4 | Molecular Dynamics Simulation |
4 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
4 | Microscopy, Electron |
4 | Mice, Inbred C57BL |
4 | Mice, Inbred BALB C |
4 | Mental Health |
4 | Mass Screening (methods) |
4 | Magnetic Resonance Spectroscopy |
4 | Italy (epidemiology) |
4 | Interprofessional Relations |
4 | Immunity |
4 | Guidelines as Topic |
4 | Genome, Viral (genetics) |
4 | Feces (microbiology) |
4 | Enzyme-Linked Immunosorbent Assay |
4 | Drug Repositioning |
4 | Drug Discovery |
4 | Drug Combinations |
4 | Cross Infection (prevention & control) |
4 | Coronavirus (immunology) |
4 | Coronaviridae Infections (veterinary) |
4 | Coronaviridae Infections (pathology) |
4 | Coronaviridae Infections (diagnosis) |
4 | Colorectal Neoplasms (complications) |
4 | Circular Dichroism |
4 | Chiroptera |
4 | Chickens |
4 | Cattle Diseases (microbiology) |
4 | Camelus (virology) |
4 | Bronchoalveolar Lavage Fluid (virology) |
4 | Biomedical Research |
4 | Betacoronavirus (chemistry) |
4 | Anxiety |
4 | Alanine (therapeutic use) |
4 | Age Distribution |
4 | Acute Disease |
4 | Access to Information |
3 | World Health Organization (organization & administration) |
3 | Viruses (genetics) |
3 | Viruses (classification) |
3 | Virus Physiological Phenomena |
3 | Virus Diseases (transmission) |
3 | Virus Diseases (diagnosis) |
3 | Viral Fusion Proteins |
3 | Viral Envelope Proteins (immunology) |
3 | Viral Envelope Proteins (analysis) |
3 | United Kingdom |
3 | Thailand |
3 | Swine Diseases (virology) |
3 | Sweden (epidemiology) |
3 | Stress, Psychological |
3 | Spike Glycoprotein, Coronavirus (metabolism) |
3 | Spike Glycoprotein, Coronavirus (immunology) |
3 | Singapore (epidemiology) |
3 | Ships |
3 | Sequence Homology, Nucleic Acid |
3 | Sequence Homology, Amino Acid |
3 | Sequence Analysis, Protein |
3 | Sequence Analysis, DNA |
3 | Science (organization & administration) |
3 | SARS Virus (metabolism) |
3 | SARS Virus (growth & development) |
3 | SARS Virus (classification) |
3 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
3 | Respiratory Syncytial Virus Infections (virology) |
3 | Respiratory Syncytial Virus Infections (veterinary) |
3 | Respiratory Insufficiency (virology) |
3 | Research |
3 | Recombinant Proteins (therapeutic use) |
3 | Rabbits |
3 | Public Health Practice |
3 | Public Health (methods) |
3 | Protein Folding |
3 | Protein Conformation |
3 | Protective Clothing |
3 | Predictive Value of Tests |
3 | Poultry Diseases (virology) |
3 | Periodicals as Topic |
3 | Paramyxoviridae Infections (epidemiology) |
3 | Pandemics (statistics & numerical data) |
3 | Open Reading Frames |
3 | Occupational Exposure |
3 | Mortality (trends) |
3 | Molecular Epidemiology |
3 | Models, Genetic |
3 | Models, Biological |
3 | Membrane Glycoproteins (immunology) |
3 | Melia azedarach |
3 | Liver (pathology) |
3 | Internet |
3 | Intensive Care Units |
3 | Influenza, Human (epidemiology) |
3 | Infectious Disease Transmission, Vertical |
3 | Infections |
3 | Immunity, Innate |
3 | Hygiene |
3 | Host Specificity |
3 | Holidays |
3 | Health Policy |
3 | Fever (virology) |
3 | Feces (virology) |
3 | Fatal Outcome |
3 | Evolution, Molecular |
3 | Evidence-Based Medicine |
3 | Epithelial Cells (virology) |
3 | Epidemiological Monitoring |
3 | Emigration and Immigration |
3 | Drug Therapy, Combination |
3 | Disease Transmission, Infectious (prevention & control) |
3 | Disease Models, Animal |
3 | Diarrhea (veterinary) |
3 | Delivery of Health Care (trends) |
3 | DNA, Viral (analysis) |
3 | Cytopathogenic Effect, Viral |
3 | Cytochrome P-450 CYP3A Inhibitors (therapeutic use) |
3 | Cysteine Endopeptidases (chemistry) |
3 | Critical Illness (therapy) |
3 | Critical Care |
3 | Cough (virology) |
3 | Coronavirus, Bovine (immunology) |
3 | Coronavirus Infections (physiopathology) |
3 | Coronavirus Infections (metabolism) |
3 | Coronavirus (physiology) |
3 | Coronavirus (pathogenicity) |
3 | Coronaviridae Infections (immunology) |
3 | Consensus |
3 | Computational Biology |
3 | Computational Biology (methods) |
3 | Communicable Disease Control |
3 | Communicable Disease Control (methods) |
3 | Commerce |
3 | Cattle Diseases (etiology) |
3 | Bronchoalveolar Lavage Fluid (microbiology) |
3 | Betacoronavirus (growth & development) |
3 | Basic Reproduction Number |
3 | Bacterial Infections (veterinary) |
3 | Asymptomatic Diseases |
3 | Antibodies, Viral (immunology) |
3 | Antibodies, Monoclonal (therapeutic use) |
3 | Antibodies, Bacterial (analysis) |
3 | Animal Husbandry |
3 | Adaptation, Psychological |
2 | Whole Genome Sequencing |
2 | Virus Shedding |
2 | Virus Diseases (drug therapy) |
2 | Viral Vaccines (therapeutic use) |
2 | Viral Vaccines (administration & dosage) |
2 | Viral Structural Proteins (genetics) |
2 | Viral Proteins |
2 | Viral Proteins (physiology) |
2 | Viral Proteins (analysis) |
2 | Viral Envelope Proteins (metabolism) |
2 | Vaccines |
2 | Vaccines, DNA (genetics) |
2 | Travel-Related Illness |
2 | Travel (legislation & jurisprudence) |
2 | Transportation |
2 | Transmissible gastroenteritis virus (isolation & purification) |
2 | Transmissible gastroenteritis virus (genetics) |
2 | Tonsillectomy |
2 | Toll-Like Receptor 7 (immunology) |
2 | Tertiary Care Centers |
2 | Telemedicine |
2 | Syndrome |
2 | Switzerland (epidemiology) |
2 | Swine Diseases (microbiology) |
2 | Sweden |
2 | Survival Rate |
2 | Substrate Specificity |
2 | State Medicine |
2 | Spectrometry, Fluorescence |
2 | Specimen Handling |
2 | Software |
2 | Social Support |
2 | Social Media |
2 | Signal Transduction |
2 | Sex Distribution |
2 | Severe Acute Respiratory Syndrome (physiopathology) |
2 | Severe Acute Respiratory Syndrome (metabolism) |
2 | Severe Acute Respiratory Syndrome (complications) |
2 | Serologic Tests (methods) |
2 | Science (economics) |
2 | Rural Population |
2 | Rotavirus Infections (veterinary) |
2 | Rotavirus Infections (diagnosis) |
2 | Ritonavir |
2 | Ribonucleotides (therapeutic use) |
2 | Rhinovirus (pathogenicity) |
2 | Respiratory Tract Infections (physiopathology) |
2 | Respiratory Tract Infections (etiology) |
2 | Respiratory Tract Infections (diagnosis) |
2 | Respiratory Tract Diseases (virology) |
2 | Respiratory Tract Diseases (veterinary) |
2 | Respiratory Tract Diseases (immunology) |
2 | Respiratory System (virology) |
2 | Respiratory Syncytial Virus Infections (transmission) |
2 | Respiratory Syncytial Virus Infections (physiopathology) |
2 | Respiratory Sounds |
2 | Respiratory Insufficiency |
2 | Respiratory Insufficiency (therapy) |
2 | Respiratory Distress Syndrome, Adult (therapy) |
2 | Renin-Angiotensin System (physiology) |
2 | Reference Standards |
2 | Recombinant Proteins |
2 | Receptors, Virus (metabolism) |
2 | Receptors, Virus (chemistry) |
2 | Random Allocation |
2 | Radiography |
2 | Racism |
2 | RNA Viruses (isolation & purification) |
2 | RNA Interference |
2 | Public Policy |
2 | Public Health Administration |
2 | Proteome |
2 | Protein Multimerization |
2 | Prospective Studies |
2 | Pregnancy Outcome |
2 | Pregnancy Complications, Infectious (prevention & control) |
2 | Pregnancy Complications, Infectious (diagnosis) |
2 | Poultry Diseases (immunology) |
2 | Population Surveillance (methods) |
2 | Polymerase Chain Reaction (methods) |
2 | Polyethylene Glycols (therapeutic use) |
2 | Pneumonia, Viral (metabolism) |
2 | Pneumonia (etiology) |
2 | Picornaviridae Infections (epidemiology) |
2 | Pharynx (virology) |
2 | Pharyngitis (etiology) |
2 | Peptidyl-Dipeptidase A (genetics) |